brexucabtagene autoleucel
gilead sciences
['car-t', 'tecartus', 'cart,(-cartitude)', 'leusm']
#asco22 #leusm pantin: existing cd19 car-t approaches show similarly high cr rates in heavily pretreated pts. cr is nice but durability is key. that will be major differentiator of all developing challengers to tecartus. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)